ProMetic Life Sciences Inc. (PLI) Receives Hold Rating from BLOOM BURTON&CO
Several other equities analysts have also commented on PLI. Royal Bank Of Canada reissued an outperform rating on shares of ProMetic Life Sciences in a research report on Wednesday, June 15th. Scotiabank reaffirmed an outperform rating and issued a C$5.00 price target on shares of ProMetic Life Sciences in a research report on Wednesday, August 10th. CIBC lowered their price target on ProMetic Life Sciences from C$5.00 to C$4.85 in a research report on Thursday, August 25th. Finally, TD Securities reaffirmed a speculative buy rating and issued a C$4.50 price target on shares of ProMetic Life Sciences in a research report on Wednesday, September 28th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. ProMetic Life Sciences has a consensus rating of Buy and an average target price of C$4.84.
Shares of ProMetic Life Sciences (TSE:PLI) remained flat at $3.10 during trading on Thursday. The stock had a trading volume of 131,216 shares. ProMetic Life Sciences has a one year low of $1.67 and a one year high of $3.62. The firm has a 50 day moving average of $2.93 and a 200-day moving average of $3.01. The firm’s market capitalization is $1.87 billion.
About ProMetic Life Sciences
ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Stock Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related stocks with our FREE daily email newsletter.